Who are REVAXIS®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Infanrix TM, RepevaxTM, Comparator: Tripedia, GSK Biologicals' DTPa-IPV/Hib vaccine, REPEVAX™ (Concomitant).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/revaxis.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

REVAXIS® — Competitive Intelligence Brief

REVAXIS® (REVAXIS®) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated combination vaccine. Area: Immunology / Infectious Disease.

phase 3 Inactivated combination vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

REVAXIS® (REVAXIS®) — Sanofi Pasteur, a Sanofi Company. REVAXIS is a combined vaccine that provides active immunization against diphtheria, tetanus, and poliomyelitis by stimulating the immune system to produce antibodies against these three pathogens.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
REVAXIS® TARGET	REVAXIS®	Sanofi Pasteur, a Sanofi Company	phase 3	Inactivated combination vaccine
Infanrix TM	Infanrix TM	GlaxoSmithKline	marketed	Inactivated combination vaccine
RepevaxTM	RepevaxTM	GlaxoSmithKline	phase 3	Inactivated combination vaccine
Comparator: Tripedia	Comparator: Tripedia	Merck Sharp & Dohme LLC	phase 3	Inactivated combination vaccine
GSK Biologicals' DTPa-IPV/Hib vaccine	GSK Biologicals' DTPa-IPV/Hib vaccine	GlaxoSmithKline	phase 3	Inactivated combination vaccine
REPEVAX™ (Concomitant)	REPEVAX™ (Concomitant)	Merck Sharp & Dohme LLC	phase 3	Inactivated combination vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated combination vaccine class)

GlaxoSmithKline · 3 drugs in this class
Merck Sharp & Dohme LLC · 2 drugs in this class
Sanofi Pasteur, a Sanofi Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). REVAXIS® — Competitive Intelligence Brief. https://druglandscape.com/ci/revaxis. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab